| Dec'19 | Dec'18 | Dec'17 | Dec'16 | |||
|---|---|---|---|---|---|---|
Revenue: | ||||||
Precision oncology testing | ||||||
180,462 | 78,407 | 42,088 | 24,496 | |||
Development services | ||||||
33,913 | 12,232 | 7,754 | 753 | |||
Revenues | ||||||
214,375 | 90,639 | 49,842 | 25,249 | |||
Costs and operating expenses: | ||||||
Cost of precision oncology testing | ||||||
62,255 | 39,846 | 28,883 | 22,065 | |||
Cost of development services | ||||||
8,465 | 3,364 | 2,735 | 59 | |||
Research and development expense | ||||||
86,292 | 50,714 | 25,562 | 10,859 | |||
Sales and marketing expense | ||||||
78,335 | 53,465 | 32,497 | 26,192 | |||
General and administrative expense | ||||||
61,399 | 36,192 | 36,777 | 9,921 | |||
Total costs and operating expenses | ||||||
296,746 | 183,581 | 126,454 | 69,096 | |||
Loss from operations | ||||||
-82,371 | -92,942 | -76,612 | -43,847 | |||
Interest income | ||||||
13,741 | 5,266 | 2,234 | 733 | |||
Interest expense | ||||||
1,181 | 1,251 | 2,702 | 3,018 | |||
Gain (Loss) on Extinguishment of Debt | ||||||
0 | 0 | -5,100 | 0 | |||
Other (expense) income, net | ||||||
88 | 4,702 | -1,059 | -1 | |||
Loss before provision for income taxes | ||||||
-69,723 | -84,225 | -83,214 | -46,133 | |||
Provision for income taxes | ||||||
-1,872 | 38 | 7 | 6 | |||
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | ||||||
-67,851 | -84,263 | -83,221 | -46,139 | |||
Net Income (Loss) Attributable to Redeemable Noncontrolling Interest | ||||||
7,800 | 800 | 0 | 0 | |||
Net loss attributable to Guardant Health, Inc. | ||||||
-75,651 | -85,063 | -83,221 | -46,139 | |||
Deemed dividend related to repurchase of convertible preferred stock | ||||||
1,100 | - | - | - | |||
Net Income (Loss) Available to Common Stockholders, Basic | ||||||
-75,651 | -85,063 | -88,995 | -46,139 | |||
Net loss per share attributable to common stockholders, basic and diluted (in usd per share) | ||||||
-0.84 | -2.80 | -7.07 | -3.53 | |||
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted (in shares) | ||||||
90,597 | 30,403 | 12,582 | 13,053 | |||
Series A Convertible Preferred Stock | ||||||
Deemed dividend related to repurchase of convertible preferred stock | ||||||
0 | 0 | 4,716 | 0 | |||
Series D Convertible Preferred Stock | ||||||
Deemed dividend related to repurchase of convertible preferred stock | ||||||
0 | 0 | 1,058 | 0 | |||